Metabolic, toxicological, and safety considerations for drugs used to treat ADHD

Bibliography

• Wilens TE, Spencer TJ. Understanding attention-deficit/hyperactivity disorder from childhood to adulthood. Postgrad Med 2010;122(5):97-109
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Text Revision Am Psychiatry Assoc; Washington, DC: 2000
   Google Scholar
• Polanczyk G, de Lima MS, Horta BL, The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-8
   PubMed Web of Science ®Google Scholar
• Kessler RC, Adler L, Barkley R, The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry 2006;163:716-23
   PubMed Web of Science ®Google Scholar
• Fayyad J, De Graaf R, Kessler J, Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 2007;190:402-9
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children – United States, 2003 and 2007. Morb Mortal Wkly Rep 2010;59(44):1439-43
   PubMedGoogle Scholar
• Cylert and generic pemoline products. FDA Public Health Advisory. Washington, DC: FDA/Center for Drug Evaluation and Research, 2005. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm151073.htm [Last accessed 10 October 2011]
   Google Scholar
• Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009;23(1):21-31
   PubMedGoogle Scholar
• Witcher JW, Long A, Smith B, Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2003;13(1):53-63
   PubMed Web of Science ®Google Scholar
• Kollins SH, Jain R, Brams M, Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.. Pediatrics 2011;127(6): doi:10.1542/peds.2010-1260
   Google Scholar
• Sallee FR, McGough J, Wigal T, Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2009;48:155-65
   PubMed Web of Science ®Google Scholar
• Musshoff F. Illegal or legitimate use? Precursor compounds to amphetamine and methamphetamine. Drug Metab Rev 2000;32(1):15-44
   PubMed Web of Science ®Google Scholar
• Kraemer T, Maurer HH. Toxicokinetics of amphetamines: metabolism and toxicokinetic data of designer drugs, amphetamine, methamphetamine, and their N-alkyl derivatives. Ther Drug Monit 2002;24:277-89
   PubMed Web of Science ®Google Scholar
• Adderall medication guide. DSM Pharmaceuticals, Inc., Greenville, NC; 2007
   Google Scholar
• Davis JM, Kopin IJ, Lemberge L, Effects of urinary pH on amphetamine metabolism. Drug Metab Man 1971;179(1):493-501
   Google Scholar
• Poklis A, Still J, Slattum PW, Urinary excretion of d-amphetamine following oral doses in humans: implications for urine drug testing. J Anal Toxicol 1998;22:481-6
   PubMedGoogle Scholar
• Dexedrine prescribing information. GlaxoSmithKline, Research, Triangle Park, NC; 2001
   Google Scholar
• Adderall XR prescribing information. Shire US Inc., Wayne, PA; 2010
   Google Scholar
• Steinkellner T, Freissmuth M, Sitte HH, The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’), methamphetamine and D-amphetamine. Biol Chem 2011;392:103-15
   PubMed Web of Science ®Google Scholar
• Greenhill L. Clinical effects of stimulant medication in ADHD. In: Soltnao MV, Arnsten AFT, Castellanos FX, editors. Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. Oxford University; New York: 2001
   Google Scholar
• Kolar D, Keller A, Golfinopoulos M, Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat 2008;4(2):389-403
   PubMedGoogle Scholar
• Zhu J, Spencer TJ, Liu-Chen LY, Methylphenidate and µ opioid receptor interactions: a pharmacological target for prevention of stimulant abuse. Neuropharmacology 2011;61:283-92
   PubMed Web of Science ®Google Scholar
• White SR. Amphetamine toxicity. Semin Respir Crit Care Med 2002;23(1):27-34
   PubMedGoogle Scholar
• MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD Follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics 2004;113:762-9
   PubMed Web of Science ®Google Scholar
• Swanson J, Greenhill L, Wigal T. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 2006;45:1304-13
   PubMed Web of Science ®Google Scholar
• Vyvanse prescribing information. Shire US Inc., Wayne, PA; 2011
   Google Scholar
• Wigal SB, Kollins SH, Childress AC, Adeyi B. Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day. Child Adolesc Psychiatr Ment Health 2010;4:32
   PubMedGoogle Scholar
• Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat 2010;6:317-27
   PubMed Web of Science ®Google Scholar
• Krishnan SM, Pennick M, Stark JG. Metabolism, distribution and elimination of lisdexamfetamine dimesylate. Clin Drug Invest 2008;28(12):745-55
   PubMedGoogle Scholar
• Goodman DW. Lisdexamfetamine dimesylate (Vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder. Pharm Ther 2010;35(5):273-87
   Google Scholar
• Ermer J, Homolka R, Martin P, Lisdexamfetamine dimesylate: linear dose-proportionality, low intersubject and intrasubject variability, and safety in an open-label single-dose pharmacokinetic study in healthy adult volunteers. J Clin Pharmacol 2010;50:1001-11
   PubMed Web of Science ®Google Scholar
• Wigal SB, Wigal TL, Kollins SH. Advances in methylphenidate drug delivery systems for ADHD therapy. Advan ADHD. 2006;1:4-7
   Google Scholar
• Lyseng-Williamson KA, Keating GM. Extended-release methylphenidate (Ritalin® LA). Drugs 2002;62(15):2251-9
   PubMed Web of Science ®Google Scholar
• Sun Z, Murry DJ, Sanghani SP, Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J Pharmacol Exp Ther 2004;310(2):469-76
   PubMed Web of Science ®Google Scholar
• Ritalin® prescribing information. Novartis Pharmaceuticals Corp., East Hanover, NJ; 2007
   Google Scholar
• Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000;75:711-21
   PubMed Web of Science ®Google Scholar
• Wigal SB, Gupta S, Greenhill L, Pharmacokinetics of methylphenidate in preschoolers with Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol 2007;17:153-64
   PubMed Web of Science ®Google Scholar
• Methylin™. Mallinckrodt, Inc., Hazelwood, MO; 2010
   Google Scholar
• Ritalin LA® prescribing information. Novartis Pharmaceuticals Corp., East Hanover, NJ; 2007
   Google Scholar
• Metadate CD. UCB, Inc., Smyrna, GA; 2007
   Google Scholar
• Concerta prescribing information. McNeil Pediatrics, Tutusville, NJ; 2010
   Google Scholar
• Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 2003;23(10):1281-99
   PubMed Web of Science ®Google Scholar
• Focalin XR prescribing information. Novartis Pharmaceuticals Corp., East Hanover, NJ; 2011
   Google Scholar
• Markowitz JS, Patrick KS. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmocol 2008;28(3):S54-61
   PubMedGoogle Scholar
• Pierce D, Dixon CM, Wigal SB, Pharmacokinetics of methylphenidate transdermal system (MTS): results from a laboratory classroom study. J Child Adolesc Psychopharmacol 2008;18(4):355-64
   PubMed Web of Science ®Google Scholar
• Daytrana prescribing information. Shire US Inc., Wayne, PA; 2010
   Google Scholar
• Bell GH, Novak AJ, Griffin WC, Transdermal and oral dl-methylphenidate-ethanol interactions in C57BL/6J mice: transesterification to ethylphenidate and elevation of d-methylphenidate concentrations. J Pharm Sci 2011;100(7):2966-78
   PubMedGoogle Scholar
• Heal DJ, Pierce DM. Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs 2006;20(9):713-38
   PubMedGoogle Scholar
• Pierce D, Katic A, Buckwalter M, Single- and multiple-dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic-release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. J Clin Psychopharmocol 2010;30(5):554-64
   PubMedGoogle Scholar
• Klein-Schwartz W. Abuse and toxicity of methylphenidate. Curr Opin Pediatr 2002;14:219-23
   PubMed Web of Science ®Google Scholar
• Pliszka SR, Matthews TL, Braslow KJ, Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006;45:520-6
   PubMedGoogle Scholar
• Wilens TE, Boellner SW, Lopez FA, Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2008;47(6):700-8
   PubMed Web of Science ®Google Scholar
• Zhu H, Patrick KS, Markowitz JS. Enantiospecific determination of dl-methylphenidate and dl-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: application to human ethanol interactions. J Chromatogr 2011;879:783-8
   Google Scholar
• Daughton JM, Kratochvil CJ. Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls. J Am Acad Child Adolesc Psychiatry 2009;48(3):240-8
   PubMedGoogle Scholar
• Chalon SA, Desager J, DeSante KA, Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin Pharmacol Ther 2003;73(3):178-91
   PubMedGoogle Scholar
• Witcher JW, Long A, Smith B, Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. J Child Adolesc Psychopharm 2003;13:53-63
   PubMed Web of Science ®Google Scholar
• Bertilsson L, Dahl ML, Dalen P, Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53:111-22
   PubMed Web of Science ®Google Scholar
• Cascorbi I. Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication. Eur J Clin Invest 2003;33(2):17-22
   PubMedGoogle Scholar
• Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;325:2211-21
   Google Scholar
• Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit-hyperactivity disorder in children and adolescents. Pediatr Drugs 2009;11(3):203-26
   PubMedGoogle Scholar
• Strattera prescribing information. Eli Lilly and Co., Indianapolis, IN; 2003
   Google Scholar
• Bangs ME, Tauscher-Wisniewski S, Polzer J, Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008;47(2):209-18
   PubMedGoogle Scholar
• Parker C. Pharmacological treatments for ADHD. Prog in Neurology and Psychiatry. 2009; published online 7 August 2009; doi: 10.1002/pnp.128
   Google Scholar
• Wernicke JF, Holdridge KC, Jin L. Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Dev Med Child Neurol 2007;49:498-502
   PubMedGoogle Scholar
• Kratochvil CJ, Mechelson D, Newcorn JH, High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses. J Am Acad Child Adolesc Psychiatry 2007;46(9):1128-37
   PubMedGoogle Scholar
• Kapvay prescribing information. Shionogi Pharma, Inc., Atlanta, GA; 2010
   Google Scholar
• Houston MC. Clonidine hydrochloride: review of pharmacologic and clinical aspects. Prog Cardiovasc Dis 1981;23(5):337-50
   PubMed Web of Science ®Google Scholar
• Larsson P, Nordlinder A, Bergendahl HTG, Lonnqvist P. Oral bioavailability of clonidine in children. Pediatr Anesth 2011;21:335-40
   PubMed Web of Science ®Google Scholar
• Ming X, Mulvey M, Mohanty S, Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders. Adolesc Health Med Ther 2011;2:105-12
   PubMedGoogle Scholar
• Vongpatanasin W, Kario K, Atlas SA, Central sympatholytic drugs. J Clin Hypertens 2011;13(9):658-61
   Google Scholar
• Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002;58(4):527-36
   PubMed Web of Science ®Google Scholar
• Wilens TE, Spencer TJ. Combining methylphenidate and clonidine. J Am Acad Child Adolesc Psychiatry 1999;38(5):614-16
   PubMed Web of Science ®Google Scholar
• Daviss WB, Patel NC, Robb AS, Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 2008;47(2):189-96
   PubMed Web of Science ®Google Scholar
• Intuniv prescribing information. Shire Pharmaceuticals, Inc., Wayne, PA; 2011
   Google Scholar
• Posey DJ, McDougle CJ. Guanfacine and guanfacine extended release: treatment for ADHD and related disorders. CNS Drug Rev 2007;13(4):465-74
   PubMedGoogle Scholar
• Muir VJ, Perry CM. Guanfacine extended-release in attention-deficit hyperactivity disorder. Drugs 2010;70(13):1693-702
   PubMed Web of Science ®Google Scholar
• Strange BC. Once-daily treatment of ADHD with guanfacine: patient implications. Neuropsychiatr Dis Treat 2008;4(3):499-506
   PubMedGoogle Scholar
• Banaschewski T, Roessner V, Dittmann RW, Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 2004;13:102-16
   PubMed Web of Science ®Google Scholar
• Palumbo DR, Sallee FR, Pelham WE, Clonidine for attention-deficit/hyperactivity disorder: I. efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008;47(2):180-8
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Polypharmacy: when is it rational? J Pract Psychiatry Behav Health 1995;1:92-8
   Google Scholar
• Niculescu AB III, Hulvershorn LA. Toward early, personalized, rational polypharmacy in psychiatry: a tri-dimensional approach. Psychopharmacol Rev 2010;45(2):9-16
   Google Scholar
• Sallee FR. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder. Postgrad Med 2010;122(5):78-87
   PubMed Web of Science ®Google Scholar
• Barbaresi WJ, Katusic SK, Colligan RC, Long-term stimulant medication treatment of attention-deficit/hyperactivity disorder: results from a population-based study. J Dev Behav Pediatr 2006;27(1):1-10
   PubMed Web of Science ®Google Scholar
• Hammerness P, Georgiopoulos A, Doyle RL, An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol 2009;19(5):493-9
   PubMed Web of Science ®Google Scholar